Opioid Pharmacology

As a partial mu receptor agonist, buprenorphine activates the mu receptor but with submaximal intrinsic efficacy — it cannot produce the same degree of receptor activation as a full agonist even at saturating doses. This property creates a ceiling effect on respiratory depression: above a certain dose, increasing buprenorphine further does not produce additional respiratory suppression. This makes buprenorphine substantially safer than full agonist opioids in overdose, and it is the pharmacological basis for buprenorphine's favorable safety profile in opioid use disorder treatment compared to methadone.

The ceiling effect on respiratory depression does not mean a ceiling on analgesia at clinically used doses — buprenorphine produces meaningful analgesia across a wide dose range. However, patients who are fully tolerant to high doses of full agonist opioids may find buprenorphine's analgesic ceiling to be a limitation when it is used as the sole analgesic for severe pain.

Buprenorphine binds to the mu receptor with extremely high affinity — higher than morphine, oxycodone, fentanyl, or most other clinically used opioids. This means buprenorphine can displace full agonists that are already occupying mu receptors. In a patient who is physically dependent on a full agonist opioid, displacement of that agonist by buprenorphine removes the receptor activation that the patient's nervous system has come to require, immediately precipitating acute opioid withdrawal. This is called precipitated withdrawal, and it is more intense and more abrupt than the gradual withdrawal that occurs when an opioid wears off naturally.

Precipitated withdrawal is the primary reason that buprenorphine induction for opioid use disorder treatment requires careful timing. The patient must be in a state of mild to moderate spontaneous withdrawal — meaning the previously used full agonist has largely cleared from the receptors — before the first dose of buprenorphine is given. If buprenorphine is given while significant full agonist receptor occupancy remains, precipitated withdrawal will occur. Low Opioid Withdrawal Scale scores serve as a practical guide to safe induction timing.

In addition to partial mu agonism, buprenorphine is a kappa receptor antagonist. Kappa receptor activation produces dysphoria, so blocking kappa receptors has an antidysphoric and potentially antidepressant effect. This kappa antagonism is thought to contribute to buprenorphine's mood-stabilizing effects in opioid use disorder treatment, which go beyond simple suppression of withdrawal symptoms.

Buprenorphine is available in several formulations with different clinical applications. Sublingual and buccal films and tablets are used for both pain management and opioid use disorder treatment. The sublingual route bypasses first-pass hepatic metabolism, though bioavailability is variable. A combination product containing buprenorphine and naloxone (Suboxone) is the most widely used formulation for opioid use disorder treatment; the rationale for adding naloxone is discussed in Section 3. Long-acting injectable buprenorphine formulations provide monthly dosing for opioid use disorder treatment and improve adherence.

Naloxone is the primary agent for acute opioid overdose reversal, covered in detail in Module 3. Its key properties bear repeating in the context of this module: it is a pure competitive antagonist at mu, kappa, and delta receptors with rapid onset (1 to 5 minutes intravenously) and short duration (30 to 90 minutes). Its short duration relative to most opioids it reverses creates the risk of resedation.

The addition of naloxone to the buprenorphine/naloxone combination product (Suboxone) exploits naloxone's poor sublingual bioavailability. When Suboxone is taken sublingually as prescribed, the naloxone component is largely not absorbed and does not interfere with buprenorphine's therapeutic effect. If a person attempts to crush and inject the tablet, however, the naloxone is fully bioavailable via the intravenous route, precipitating immediate withdrawal in any opioid-dependent individual. This formulation strategy substantially reduces the diversion and injection misuse of buprenorphine.

Naltrexone is a pure opioid antagonist with a longer duration of action than naloxone, making it suitable for once-daily oral dosing or monthly extended-release injectable administration. Unlike naloxone, which is used primarily for acute overdose reversal, naltrexone is used for long-term maintenance treatment of both opioid use disorder and alcohol use disorder.

For opioid use disorder, naltrexone blocks the rewarding effects of any opioid taken on top of it, extinguishing the reinforcement that drives continued use. Its critical requirement is that the patient must be fully detoxified from opioids before starting naltrexone — typically a minimum of 7 to 10 days free of short-acting opioids and longer for methadone. If naltrexone is given to a patient with residual opioid dependence, it will precipitate severe withdrawal. There is no way to gradually introduce naltrexone as there is with buprenorphine induction.

Extended-release injectable naltrexone (given as a monthly intramuscular injection) substantially improves adherence compared to daily oral naltrexone, because the patient cannot choose to stop taking it on a day they want to use opioids. This formulation is preferred when patient engagement and adherence are concerns and when the patient has successfully completed detoxification.

Methylnaltrexone and naloxegol are peripherally restricted opioid antagonists designed to treat opioid-induced constipation without reversing central analgesia. They block peripheral mu receptors in the gut — restoring normal bowel motility — but do not cross the blood-brain barrier in meaningful amounts and therefore do not reverse the central analgesic or other central nervous system effects of opioids. These agents are used specifically for opioid-induced constipation in patients on chronic opioid therapy when standard laxatives have been insufficient.